EUCTR2010-019139-36-IT进行中（未招募）不适用
RTaxot: Docetaxel-based concurrent chemo-hormono-radiation in high and very high-risk prostate cancer patients: a phase II multicenter trial - RTaxot
AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE0 个研究点开始时间: 2010年4月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Histologically proven adenocarcinoma of the prostate 2. Prostate cancer patients with two or more of the following prognostic factors: cT2b or T2c or Gleason Score (GS) = 7 or PSA between 10 and 20 ng/ml 3. Prostate cancer patients with High Risk of Recurrence according to NCCN definition :cT3a or GS = 8-10 or PSA > 20 ng/ml 4. Prostate cancer patients with Very High Risk of Recurrence according to NCCN definition(6- NCCN): cT3b-T4 or patients with multiple adverse factors included into the definition of High Risk
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.cN1 patients 2.Patients with history of prior invasive malignant cancer(s) within the last 5 years except adequately treated or controlled basal cell or squamous cell carcinoma of the skin. 3.Patients with history of previous radiotherapy to the abdomen or pelvis 4.Patients with history of previous chemotherapy (during preceding two years) 5.Uncontrolled diabetes 6.Inflammatory Bowel Diseases (Crohn`s disease, ulcerative colitis), acute diverticulitis, diverticulosis of the sigma
研究者
相似试验
已完成
不适用
eo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcergastric cancerJPRN-UMIN000015632Department of Frontier Surgery, Graduate school of Medicine, Chiba University20
进行中（未招募）
不适用
DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) - DOPERLOMetastatic (stage IV) non-small cell lung cancer (NSCLC) who have not previously been treated with anticancer drugsEUCTR2007-001555-19-GRHellenic Cooperative Oncology Group
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006381-29-DEniversitätsmedizin Mainz200
已完成
不适用
Docetaxel and Trastuzumab therapy or maximal androgen blockade for patients with recurrent and/or metastatic salivary grand carcinomaHER2 and/or androgen receptor positive recurrent and/or metastatic salivary gland carcinomaJPRN-UMIN000009437International University of Health and Welfare Mita Hospital30
已完成
不适用
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.Breast cancerJPRN-UMIN000002310Gunma Breast Cancer Research Group 2 surgery90